Aguilar-Olivos N, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 15
Paginas: 4-6
Archivo PDF: 71.86 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diab Care 2007; 30: 734-43.

2. Kobashi-Margáin RA, Gutiérrez-Grobe Y, Ponciano-Rodríguez G, Uribe M, Méndez-Sánchez N. Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico. Ann Hepatol 2010; 9: 282-8.

3. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20(1 Pt. 1): 119-25.

4. Henning JR, Graffeo CS, Rehman A, Fallon NC, Zambirinis CP, Ochi A, Barilla R, et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology 2013; 58: 589-602.

5. Zimmermann, et al. Functional Contribution of Elevated Circulating and Hepatic Non-Classical CD14+CD16+ Monocytes to Inflammation and Human Liver Fibrosis. PLoS ONE 2010; 5: e11049.

6. Global status report on noncommunicable diseases 2010. Geneva, World Health Organization; 2011.

7. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816.

8. De Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 584-91.

9. Demyen M, Alkhalloufi K, Pyrsopoulos NT. Lipid-lowering agents and hepatotoxicity. Clin Liver Dis 2013; 17: 699- 714.

10. Cohen D, Anania F, Chalasani N. An assessment of statin safety by hepatolo-gists. Am J Cardiol 2006; 97: C77-C81.

11. Teschke R. Hepatotoxicity associated with statins. Ann Hepatol 2012; 11: 418-20.

12. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.

13. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273, e1261.

14. García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez- Rosado R, Carbó J, Asensi V, Soriano V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-83.

15. Kramer JR, Giordano TP, El-Serag HB. Effect of human immuno-deficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol 2007; 5: 1321-8.